Details of HTA journal title
Last updated: 9 March 2010 - Next update due: 16 March 2010
Research type: |
HTA Technology Assessment Report |
Title (lead author) etc: |
Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation (Ara) 118 pages, Volume 13, number 34 |
DOI |
10.3310/hta13340 |
View/print executive summary
View/print abstract
View full text in pdf format (804 KB) This title is available on our CD-ROM of the journal. Order a CD-ROM - free of charge worldwide.
Go to our correspondence page to comment on this publication
|
|
Headline: |
Study found that rosuvastatin 40 mg/day is the most effective treatment in terms of lowering low-density lipoprotein cholesterol and is the optimal treatment for individuals with a recent history of acute coronary syndrome using a threshold of £20,000 per QALY. However, if the cost of atorvastatin decreases when the patent ends in 2011, atorvastatin 80 mg/day will become the most cost-effective treatment for all thresholds |
Project ref: |
07/03/01 |
Original project title: |
Early high dose lipid-lowering therapy to avoid cardiac events |
Chief Investigator: |
School of Health and Related Research (ScHARR-TAG), University of Sheffield |
Start Date: |
January 2008 |
Publication date: |
July 2009 |
Cost: |
This project was commissioned by the HTA programme on a call-off contract basis. |
Project Protocol: |
Project protocol (pdf format, 155 kbytes) |
Printed copies of this title despatched: |
96 (Figures relate to the previous calendar month) |
Downloads/Views of electronic version from website: |
8734 (Figures are cumulative.) Last updated 12th January 2010. |
URL of this page: |
http://www.hta.ac.uk/1700 |
News feeds